Saralasin acetate test in renal transplant hypertension. Report of 17 cases and a review of the literature.
The saralasin acetate test was performed in 17 hypertensive patients with renal transplants. These results were compared with 39 previously published reports of transplant patients who had been tested in the same manner. Eighty-two percent of our patients had a positive saralasin acetate test, suggesting renin-dependent hypertension. Baseline plasma renin activity (PRA) was significantly higher in patients with positive tests (6.96 +/- 1.75 v 2.88 +/- 0.53 ng/mL/hr). However, positive tests were obtained in several patients who had normoreninemia, and PRA levels did not correlate with the magnitude of vasodepressor BP response to saralasin. Transplant artery stenosis, acute rejection, and chronic rejection were the most common posttransplant complications associated with a positive test, but several patients had hypertension alone. While highly sensitive for renin-dependent hypertension posttransplantation, the test had poor specificity for identification of any one cause of posttransplant hypertension.
D001794:Blood Pressure / Q000187:drug effects; D005500:Follow-Up Studies; D006084:Graft Rejection; D006801:Humans; D006977:Hypertension, Renal / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000175:diagnosis; D012078:Renal Artery Obstruction / Q000175:diagnosis / Q000209:etiology; D012083:Renin / Q000097:blood; D012504:Saralasin
D012083:Renin; D012504:Saralasin